Christine Lightfoot, NP
Adult Health · Kansas City, MONPI 1457507352
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Organon at 37.4% of the total. Reporting peaked in 2024 at $3,658 and has fallen 79.2% since, to $763 in 2025. Among adult health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $45.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$2K
- Intuitive Surgical$942
- Novo Nordisk$553
- Gilead$509
- Viiv Healthcare Company$350
- Amgen$225
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$2,31938%
- Travel & lodging$94215%
- Food & beverage$2,88547%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 6 | $2,299 |
| Intuitive Surgical | 3 | $942 |
| Novo Nordisk | 15 | $553 |
| Gilead | 31 | $509 |
| Viiv Healthcare Company | 15 | $350 |
| Amgen | 8 | $225 |
| GSK | 6 | $195 |
| Lilly USA, LLC | 8 | $167 |
| Exact Sciences | 4 | $152 |
| AbbVie | 7 | $141 |
| Pfizer | 4 | $80 |
| Merck | 4 | $59 |
| Napo Pharmaceuticals Inc | 4 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $51 |
| Novavax Inc | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Indivior Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $29 |
| Bayer | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $22 |
| Coopersurgical, Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,145 in reported general payments places this provider in the 90th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 21 | $29,271 |
| JanuviaSitagliptin Phosphate | 17 | $27,235 |
| OzempicSemaglutide | 24 | $26,317 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,772 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 16 | $3,338 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 11 | $3,226 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,817 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $741 |
| Levothyroxine Sodium | 47 | $735 |
| Atorvastatin Calcium | 101 | $679 |
| Amlodipine Besylate | 75 | $592 |
| Omeprazole | 26 | $466 |
| Pantoprazole Sodium | 29 | $445 |
| Lisinopril | 60 | $413 |
| Rosuvastatin Calcium | 34 | $406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $167 | $29,27121 claims |
| MerckJanuvia | $59 | $27,23517 claims |
| Novo NordiskOzempic | $553 | $26,31724 claims |
| GSKShingrix | $195 | $3,33816 claims |
| PfizerAbrysvo | $80 | $3,22611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 555 adult health providers in Missouri.
Other adult health in Kansas City
- Yolanda Thompson MartinKansas City$32K
- Margaret CostelloKansas City$11K
- Nancy StepanekKansas City$8K
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Patrick BehnkeChesterfield$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.